Tobevibart not checked
Vir Biotechnology, Inc. · VIR-3434 · BRII-877
FollowEvery change as it happens, and a Monday email
Trials
4 active
9 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- Tested for
- Viral Hepatitis (3 trials), Hepatitis D, Chronic
- Main trialPhase 3
- “This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.”In the company’s words, NCT06903338 on ClinicalTrials.gov
- Other names
- VIR-3434 · BRII-877
Other drugs for Viral Hepatitis
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- Bemnifosbuvir/RuzasvirAtea Pharmaceuticals, Inc. · Phase 3
- ElebsiranVir Biotechnology, Inc. · Phase 3
- In-House Recombinant Hepatitis B vaccinePT Bio Farma · Phase 3
- BrelovitugMirum Pharmaceuticals, Inc. · Phase 3
Coming up3
- DecPhase 3 trial completes · ClinicalTrials.gov
- Mar 2029Phase 2 trial completes · ClinicalTrials.gov
- Nov 2031Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovCompletion date moved: 2026-11 to 2029-03 · ClinicalTrials.gov NCT07142811
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Sep 2026 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | |
| Phase 3Active, not recruiting | Dec 2026 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | |
| Phase 2Active, not recruiting | Mar 2029 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | |
| Phase 2Active, not recruiting | Nov 2031 | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | |
| Phase 2Completed | 16 Mar 2026 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | |
| Phase 1/2Completed | 15 Oct 2024 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | |
| Phase 1Completed | 24 Oct 2022 | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection | |
| Phase 1Completed | 9 Dec 2025 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | |
| Phase 1Completed | 31 Mar 2026 | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026